<DOC>
	<DOCNO>NCT02620592</DOCNO>
	<brief_summary>This First Human ( FIH ) Phase I study intend evaluate safety , tolerability , pharmacokinetics pharmacodynamics ZYDPLA1 normal healthy adult volunteer .</brief_summary>
	<brief_title>Clinical Study Evaluate Safety , Tolerability Pharmacokinetics ( PKs ) ZYDPLA1 Following Oral Administration Healthy Volunteers</brief_title>
	<detailed_description>Glucose-dependent insulinotropic polypeptide ( GIP ) Glucagon-like peptide ( GLP-1 ) incretin hormone , stimulate glucose dependent insulin secretion , inhibit glucagon secretion , delay gastric emptying , suppress appetite improve peripheral glucose uptake disposal . Dipeptidyl peptidase-IV ( DPP-IV ) serine protease , selectively cleave first two amino acid GIP GLP-1 thereby make inactive . Inhibition DPP-IV activity elevate endogenous GIP , GLP-1 insulin level thereby improve glucose excursion exhibit antidiabetic activity . Since orally active GLP-1 agonist available , clinically orally bioavailable DPP-IV inhibitor hold great potential treatment type 2 diabetes mellitus . Cadila Healthcare Ltd. develop novel orally bioavailable DPP-IV inhibitor ( ZYDPLA1 ) . In-vitro study confirm selective DPPIV inhibitory activity ZYDPLA1 . Pre-clinical vivo pharmacodynamic , absorption , distribution , metabolism excretion ( ADME ) &amp; toxicological study show promising antidiabetic activity , good exposure safety profile ZYDPLA1 ( various animal model ) . Hence randomize , double-blind , placebo-controlled first man trial propose evaluate safety tolerability ZYDPLA1 healthy volunteer . This study include 4 plan : ) single dose escalation study ii ) multiple dose escalation study , iii ) gender effect study iv ) food effect study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>1 . Healthy male female 18 65 year age . 2 . Male subject must agree use one contraception method study . Male contraceptive option include : Vasectomy , Abstinence require use contraceptive become sexually active , double barrier method ( condom spermicide , diaphragm cervical cap ) . No Sperm donation least 90 day last investigational product . 3 . BMI within range 18.0 30.0 kg/m2 BMI value round one significant digit decimal point . BMI value round nearest integer ( ex . 30.4 round 30 , 17.5 round 18 ) . 4 . Capable give write informed consent , include compliance protocol . 5 . Corrected QT interval ( QTc ) interval &lt; 450msec ( measure QTcF ) 6 . For gender effect study , females history sterility least 1 year menopause use long act non hormonal contraceptive measure ( e.g. , intrauterine device ) recruit . Surgical sterility define either bilateral tubal ligation/occlusion , bilateral oophorectomy hysterectomy . 7 . Negative Urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiates , methadone phencyclidine within 28 day prior initiation study prior checkin . 1 . Presence history pancreatitis time { Serum Amylase/Serum Lipase significant upper normal limit ( ≥1.5 time UNL ) } 2 . Presence history severe gastrointestinal disease last 6 month 3 . Presence history renal insufficiency time { Serum creatinine upper normal limit ( UNL ) } 4 . Active liver disease and/or liver transaminases great 1.5 time UNL 5 . History presence systemic disorder disease ( e.g. , respiratory , gastrointestinal , endocrine , immunological , dermatological , neurological , psychiatric disease body system involvement ) 6 . History presence medication last 14 day 7 . History presence significant alcoholism drug abuse within past 1 year 8 . History presence significant smoking ( 10 cigarette per day ) consumption tobacco product ( 10 time per day ) 9 . Difficulty donate blood difficulty accessibility vein . 10 . Intolerance venipuncture . 11 . Systolic blood pressure 150 mmHg less 100 mmHg diastolic blood pressure 90 mmHg 12 . Pulse rate le 50/minute 100/minute 13 . Any clinically significant laboratory finding screen 14 . History presence clinically significant electrocardiogram ( ECG ) abnormalities screen determine Principal Investigator . 15 . Major illness and/or major surgery last 3 month 16 . Volunteers participate drug research study present trial within past 30 day ( Subjected Insurance subject participate long acting drug include new biological entities/new chemical entities/biosimilar product ) . 17 . Volunteers donate one unit ( 450 mL ) blood past 3 month 18 . Positive Alcohol breath analyzer time Screening Checkin 19 . A positive hepatitis screen ( include subtype B C ) and/or positive test result HIV antibody . 20 . Any food allergy , intolerance , restriction special diet , opinion Principal investigator Subinvestigator , could contraindicate study participant 's participation study . 21 . For gender effect study , female volunteer follow criterion recruit : History pregnancy lactation past 3 month Fertile female volunteer protect pregnancy adequate longterm antifertility measure History less 1 year menopause use adequate longterm antifertility measure Using hormonal contraceptive Using hormone replacement therapy Unable give assurance protection pregnancy 3 month participation trial Positive urine pregnancy test day checkin ( woman child bear potential ) Positive serum βhuman chorionic gonadotropin ( hCG ) level screen visit ( woman child bear potential )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Healthy Subject</keyword>
	<keyword>ZYDPLA1</keyword>
	<keyword>DPPIV inhibitor</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>